TMO · Thermo Fisher Scientific Inc
Price
Snapshot
50 fields · last close| Market Cap | $242.1B |
| P/E | 34.76 |
| Float | 371.0M |
| Beta | 0.86 |
| Volatility | 21.5% |
| Exchange | NYSE |
| Sector | Life Sciences Tools & Services |
| Cap tier | Mega cap |
| Macro sensitivity | Moderate |
| Clavix score | 79.0 |
| Price | 654.80 |
| Change | +0.00% |
| Prev Close | 654.80 |
| Open | 654.15 |
| Day Low | 648.29 |
| Day High | 659.47 |
| Avg Vol | 2 |
| Avg $ Vol | $1.38B |
| 52W High | 683.63 |
| 52W Low | 435.27 |
| 52W Pos | 88.4% |
| From High | −4.22% |
| From Low | +50.44% |
| Max DD 1Y | −31.45% |
| Spread | 0.10% |
| Liquidity | Deep |
| SMA 20 | +1.32% |
| SMA 50 | +6.05% |
| SMA 200 | +20.68% |
| RSI (14) | 56.6 |
| Vol 30D | 23.5% |
| Vol 90D | 31.1% |
| 1Y Range | 435–684 |
| Daily bars | 526 |
| Perf Week | −2.99% |
| Perf Month | +7.60% |
| Perf Quarter | +26.51% |
| Perf Half Y | +33.24% |
| Perf Year | +23.38% |
| Perf YTD | +10.51% |
| Prev Day | +0.00% |
| Clavix | B+ |
| Debt / Eq | 0.73 |
| Curr Ratio | 1.89 |
| Int Cover | 15.7× |
| FCF Margin | 14.1% |
| Rev Growth | +3.9% |
| Profit | Profitable |
| Leverage | Moderate |
| Sector rank | 4 / 19 |
What TMO does
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally.
It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services.
The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases.
Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories.
The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings.
Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research.
It has strategic collaboration with genedrive plc to develop a CYP2C19 pharmacogenetic in vitro diagnostic test.
Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
Clavix risk grade
regraded every trading dayTMO grades B+, 79.0 of 100. Steadiest on Macro Resilience (67), most exposed on News Sentiment (51, mixed). 2 of the 4 weighted dimensions sit above the Life Sciences Tools & Services median. Ranks 4 of 19 in Life Sciences Tools & Services by Clavix score.
How rough the ride is
| TMO | Life Sciences Tools & Services median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.86 | 1.18 |
| Volatilityannualized | 21.5% | 29.4% |
| Max drawdown, past yearworst peak-to-trough fall | −31.5% | — |
| Typical daily movemedian absolute daily change | 0.96% | — |
| Days beyond ±3%of the last 252 sessions | 17 (7%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| TMO | Life Sciences Tools & Services median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.86 | 1.18 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Moderate 47% of 19 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Life Sciences Tools & Services names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| TMO | |
|---|---|
| 1 week | −3.0% |
| 1 month | +7.6% |
| Year to date | +10.5% |
| 1 year | +23.4% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| TMO | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 5 Aug |
| Average score0 most bearish, 100 most bullish | 67 |
| Bullish · bearisharticles above 60 · below 40 | 24 · 1 |
| Directionarticles whose tone is improving vs worsening | 24 ↑ 1 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 19 Life Sciences Tools & Services names Clavix covers; the tick is the sector median.
Growth
| TMO | |
|---|---|
| Revenue growthyear over year | +3.9% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Life Sciences Tools & Services median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openOn September 23, Thermo Fisher launched the Gibco CHO-K1 Catalog Panel, a ready-to-use set of cell nutrients for companies growing CHO-K1 cells (a common cell line used to manufacture biologic medicines and their lower-cost copies). The product comes in liquid and dry powder form and is made to current pharmaceutical manufacturing standards. The article body is cut off, so no further details about revenue or margin impact are provided.
Thermo Fisher announced three updates this month: a ready-to-use panel of CHO-K1 cell lines (used to manufacture biologic drugs) for its Gibco bioprocessing line, a deal to resell Evosep's Eno protein-analysis instrument, and expanded work with Biodesix and Memorial Sloan Kettering on blood-based cancer tests that detect leftover tumor DNA.
An analysis piece compares the growth outlooks of Gilead Sciences and Thermo Fisher Scientific. It says Gilead's growth is driven by its expanding HIV medicines, while Thermo Fisher is starting to benefit from increased customer activity across its life-sciences markets.
Biodesix (BDSX) said it made progress in two collaborations to detect cancer DNA in blood after treatment, working with Bio-Rad and Thermo Fisher.
Thermo Fisher Scientific launched the Gibco CHO-K1 Catalog Panel, a manufacturing-ready cell culture media set aimed at companies developing biologic drugs and biosimilars (near-copy versions of biologic medicines). The stock sits at $665.30, up 5.81% over 30 days and 31.55% over 90 days.
Nearest peers by size
Life Sciences Tools & Services| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| DHR | Danaher Corp | B | $150.5B | 37.58 | 0.79 | Compare |
| A | Agilent Technologies Inc | B | $47.30B | 32.85 | 1.25 | Compare |
| WAT | Waters Corp | B+ | $43.82B | 258.85 | 1.16 | Compare |
| IQV | IQVIA Holdings Inc | B | $42.50B | 30.91 | 1.18 | Compare |
| ILMN | Illumina Inc | B- | $41.23B | 49.97 | 1.43 | Compare |
| MTD | Mettler-toledo International Inc | B+ | $29.78B | 32.88 | 1.20 | Compare |
| WST | West Pharmaceutical Services Inc | A- | $23.90B | 46.80 | 1.15 | Compare |
| RVTY | Revvity Inc | B | $16.91B | 71.18 | 1.09 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.